← All trials
NCT01234558
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Jun 1, 2012
- Completion date
- Jul 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 115
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- NaurexLead sponsor
- NaurexStudy director
- Artemis Institute for Clinical ResearchOverall official - principal investigator
- CNRI-LA, Pico Rivera CAOverall official - principal investigator
- CRI-WW Lordes Hospital, Willingboro NJOverall official - principal investigator
- Claghorn-Lesem Research Clinic, Houston TXOverall official - principal investigator
- ClinilabsOverall official - principal investigator
- Lehigh Center for Clinical ResearchOverall official - principal investigator
- Lynn Health Science InstituteOverall official - principal investigator
- The University of Texas, DallasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.